Acta Clinica Belgica最新文献

{"title":"Case report: Tuberculosis versus immune-related bronchiolitis under immune checkpoint inhibitor - a diagnostic challenge.","authors":"Clara Moreno, Nieves Martinez Chanza, Lou Gonzalez Garcia, Ana Veron Sanchez, Maxime Ilzkovitz, Aspasia Georgala","doi":"10.1080/17843286.2026.2665158","DOIUrl":"https://doi.org/10.1080/17843286.2026.2665158","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs) improve survival in multiple malignancies but may induce immune-related adverse events (irAEs), including immune-related bronchiolitis (IRB). Radiologic patterns frequently overlap with infectious diseases, particularly tuberculosis (TB), whose reactivation risk may be increased by ICIs via disruption of granuloma integrity. Differentiation between IRB and TB is challenging, especially in patients from endemic areas.</p><p><strong>Case presentation: </strong>We report the case of a 53-year-old Turkish man with metastatic clear-cell renal cell carcinoma, who underwent right nephrectomy followed by nivolumab plus ipilimumab. Four months after treatment, he developed fatigue, dyspnea, productive cough, and weight loss. Chest CT scan showed centrilobular nodules with a tree-in-bud pattern. QuantiFERON® testing was positive. Bronchoalveolar lavage showed lymphocyte predominance with no infectious or neoplastic cells. Transbronchial biopsy demonstrated non-caseating granulomas. PCR for Mycobacterium tuberculosis was negative, and cultures were pending. Given the overlap between IRB and TB, empirical quadruple anti-TB therapy and inhaled corticosteroids were initiated and immunotherapy was temporarily discontinued. After 2 months, given negative mycobacterial cultures and significant hepatotoxicity, isoniazid was discontinued, rifampicin was carefully reintroduced under close monitoring, and the total anti-TB treatment duration was shortened to 4 months. The patient subsequently showed gradual improvement in respiratory symptoms, biomarkers, and radiologic findings.</p><p><strong>Conclusion: </strong>This case illustrates the challenge of distinguishing IRB from TB in ICI-treated patients. Empirical anti-TB therapy may be warranted in high-risk settings despite absent microbiological confirmation but carries toxicity and complicates oncologic management. Pre-treatment latent TB screening and multidisciplinary decision-making are essential to balance infection control with cancer therapy.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-6"},"PeriodicalIF":0.9,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belgian recommendations for tissue diagnosis of amyloidosis.","authors":"Amélie Dendooven, Annelore Vandendriessche, Priyanka Joseph Koshy, Frank Timmermans, Marijn Speeckaert, Nicolas Kint, Lucas Van Aelst, Marie-Christiane Vekemans, Nathalie Meuleman, Anne-Catherine Pouleur, Antoine Bondue, Steven Droogmans, Philippe Debonnaire, Jan De Bleecker, Amaryllis Van Craenenbroeck, Rodrigo Gallardo, Joost Schymkowitz, Frédéric Rousseau, Francis Impens, Simon Devos, Michel Delforge","doi":"10.1080/17843286.2026.2660739","DOIUrl":"https://doi.org/10.1080/17843286.2026.2660739","url":null,"abstract":"<p><strong>Background: </strong>Amyloidosis is a disorder caused by the extracellular deposition of misfolded protein fibrils, leading to organ dysfunction. Diagnosis remains challenging due to non-specific clinical presentations and the diversity of amyloid subtypes. Accurate identification of the amyloid precursor protein is key for prognostication and treatment strategy.</p><p><strong>Objectives: </strong>This document aims to provide practical recommendations for the tissue diagnosis of amyloidosis within the Belgian healthcare context. It targets clinicians managing amyloidosis patients and pathologists evaluating biopsies with suspected amyloid deposits.</p><p><strong>Methods: </strong>A structured PubMed search ('amyloidosis AND biopsy AND stain*'; 'amyloidosis AND mass spectro*') was conducted in August 2025. After exclusion of case reports, preclinical studies, and Alzheimer-related articles, 298 publications were reviewed. Recommendations were formulated based on available evidence and discussed among Belgian clinical and pathology experts.</p><p><strong>Results: </strong>Key recommendations emphasize that tissue biopsies remain essential for amyloidosis diagnosis and typing. Congo red staining with birefringence and fluorescence confirmation is required. Immunohistochemistry and immunofluorescence are first-line subtyping tools, while mass spectrometry serves as a reference method when results remain inconclusive. Centralization of complex analyses in experienced centres is encouraged.</p><p><strong>Conclusions: </strong>These recommendations promote standardized, early and accurate tissue diagnosis of amyloidosis in Belgium, supporting optimal patient management and harmonization of diagnostic practices across institutions.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-14"},"PeriodicalIF":0.9,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized antiplatelet therapy: a scoping review on the role of platelet function testing and genotyping in acute coronary syndrome.","authors":"Jeenal Venissa Rebello, Ashna Shah, Mohammed Salim Karattuthodi, Chun-Wai Mai, Mohamed Hassan Elnaem","doi":"10.1080/17843286.2026.2653688","DOIUrl":"https://doi.org/10.1080/17843286.2026.2653688","url":null,"abstract":"<p><strong>Background: </strong>Acute coronary syndrome (ACS) remains a leading cause of global morbidity and mortality, often managed with antiplatelet therapy. However, variability in patient response due to comorbidities, genetic polymorphisms, and resistance to antiplatelet agents creates challenges in optimizing treatment.</p><p><strong>Methods: </strong>The scoping review was conducted using Arksey and O'Malley's five-step framework to identify facilitators and challenges influencing the use of Platelet Function Test (PFT) and genotype-guided antiplatelet therapy for ACS. PubMed, Embase, and Scopus were utilized for identifying the relevant articles published between 2010 and 2025.</p><p><strong>Results: </strong>A total of 346 studies was included, with sample sizes ranging from 13 to 10,048 patients. The included studies showed heterogeneity in study design, sample size, follow-ups, PFT techniques and in outcomes. The articles had predominantly male patients with various comorbidities. The PFTs identified included VerifyNow, light transmission aggregometry (LTA), vasodilator-stimulated phosphoprotein (VASP), multiplate, thromboelastography (TEG) etc. The facilitating factors for PFT included risk stratification for bleeding and ischemic events and treatment adjustments in high-risk groups. Whereas the key challenges identified were lack of assay standardization, discordance between test results, and variability across testing modalities. Although the association between treatment response and genetic polymorphisms were frequently reported, evidence for clinical outcome remains variable and uncertain.</p><p><strong>Conclusion: </strong>Existing evidence shows that PFT and genotyping may provide significant findings for tailoring antiplatelet therapy in ACS. However the heterogeneity and practical challenges limit their routine use. Further, well-designed outcome driven studies and standardised protocols are required to define their role in precision guided therapy for ACS management.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-14"},"PeriodicalIF":0.9,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database.","authors":"Hong Zhou, Tingting Chen, Ting Wei, Jinhua Zhang","doi":"10.1080/17843286.2026.2655844","DOIUrl":"https://doi.org/10.1080/17843286.2026.2655844","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the overall and haemorrhagic safety profile of ramucirumab based on Food and Drug Administration Adverse Event Reporting System (FAERS) database.</p><p><strong>Methods: </strong>A retrospective disproportionality analysis using reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) was performed to evaluate adverse event reporting associated with ramucirumab.</p><p><strong>Results: </strong>A total of 7901 AEs of ramucirumab and 233 risk signals involving 19 system organ classes (SOCs) were identified. The main AEs associated with ramucirumab including haemorrhage, gastrointestinal perforations, and proteinuria were consistent with the package insert. New potential unexpected AEs including interstitial lung disease, pyogenic granuloma, osteonecrosis of the jaw, and myelodysplastic syndrome should be paid more attention. Subgroup analysis of 490 cases of ramucirumab-associated haemorrhage revealed that positive signals were distributed across 8 SOCs with 32 positive signals, with unexpected signals found in nervous system, renal and urinary, and eye disorders. Additionally, more than half of AE cases occurred within the first month with a median onset time of 27 days.</p><p><strong>Conclusion: </strong>This study outlines the post-marketing safety profile of ramucirumab, identifying unexpected signals that warrant further investigation, including a newly described subgroup of ramucirumab-induced haemorrhage.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-13"},"PeriodicalIF":0.9,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147724201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DMARDs and gout therapy in patients with chronic arthritis and end-stage renal disease: a descriptive guide.","authors":"Hebe Stuer, Johan De Meester, Barbara Neerinckx","doi":"10.1080/17843286.2026.2654069","DOIUrl":"https://doi.org/10.1080/17843286.2026.2654069","url":null,"abstract":"<p><strong>Objectives: </strong>The coexistence of chronic arthritis - here defined as rheumatoid arthritis, spondyloarthritis and gout - and end-stage renal disease (ESRD) is clinically relevant, underscoring the need for safe medication choices and dosage adjustments. However, drug use in dialysis patients is challenging, as it requires balancing treatment efficacy - potentially reduced by drug removal during dialysis - with the risks associated with impaired renal function, such as overdose and drug toxicity. In the absence of evidence-based guidelines, this paper aims to summarize the existing literature and offer a descriptive guide for the use of DMARDs and gout therapy in ESRD patients with chronic arthritis.</p><p><strong>Methods: </strong>A literature search using three different databases (Cochrane, PubMed and Embase) was conducted, yielding 41 articles.</p><p><strong>Results: </strong>In patients with ESRD, methotrexate is contraindicated, leflunomide appears safe and effective, sulfasalazine and hydroxychloroquine are not recommended because of inconsistent data. Biological DMARDs are considered safe and effective, with existing evidence likely applicable to the entire class. Limited data exist for targeted synthetic DMARDs. However, apremilast appears relatively safe, whereas JAK inhibitors are generally not recommended because of an increased cardiovascular risk. For gout patients on dialysis, urate-lowering therapy is often required. It is recommended to initiate treatment with a lower dose of allopurinol or febuxostat, both of which are effective and well tolerated. Colchicine also appears to be safe at low doses in patients on hemodialysis.</p><p><strong>Conclusion: </strong>Treatment decisions in ESRD patients with chronic arthritis should be individualized, with strict monitoring.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-14"},"PeriodicalIF":0.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing the national guidelines for pyelonephritis against the local setting in a Belgian secondary care emergency department.","authors":"Simon Fagart, Reza Soleimani, Sebastien Van de Velde, Charles Descamps","doi":"10.1080/17843286.2026.2653687","DOIUrl":"https://doi.org/10.1080/17843286.2026.2653687","url":null,"abstract":"","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"1-3"},"PeriodicalIF":0.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium.","authors":"Els Van Nieuwenhuysen, Stephanie Henry, Katoo Muylle, Wim Demey, Christine Gennigens","doi":"10.1080/17843286.2025.2608786","DOIUrl":"10.1080/17843286.2025.2608786","url":null,"abstract":"<p><strong>Objectives: </strong>Data about the clinical management of patients with ovarian cancer (OC) in real-world settings are scarce. This study documents baseline characteristics, treatments, and clinical outcomes in a real-world population of women with newly diagnosed advanced-stage OC in Belgium.</p><p><strong>Methods: </strong>This observational study, conducted at four hospitals in Belgium, retrospectively enrolled 120 women with FIGO (International Federation of Gynecology and Obstetrics classification) stage III or IV high-grade serous or endometrioid OC diagnosed between 2007 and 2018. Treatment outcomes, response to therapy, and patient survival were followed up until 20 months after diagnosis.</p><p><strong>Results: </strong>Of 113 patients with a clinical response assessment, 49.6% were diagnosed with a stage IV disease, 53.1% underwent interval debulking surgery, 98.2% received any type of chemotherapy, and 35.4% received bevacizumab. Deleterious mutations in breast cancer susceptibility genes <i>(BRCA1/BRCA2)</i> were detected in 12/84 (14.3%) patients. After primary or interval debulking surgery, 50.0% and 60.0% of stage III, and 66.7% and 80.0% of stage IV patients had no visible residual disease, respectively. Following chemotherapy, 59.3% of patients had complete clinical response and/or no visible residual disease. Until month 20 of follow-up, 37.2% of patients were disease-free.</p><p><strong>Conclusion: </strong>Until 2018, surgical resection followed by first-line chemotherapy and bevacizumab use comprised the cornerstone therapy for newly diagnosed FIGO stage IV OC in Belgium. Clinical response and progression-free survival rates were relatively high. The patients' <i>BRCA1/BRCA2</i> status was insufficiently characterized, likely reflecting the lack of perceived relevance of <i>BRCA1/BRCA2</i> mutations for OC treatment before adoption of targeted therapies in clinical practice.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"95-105"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview and resistance profiles of isolated pathogens in women with uncomplicated urinary tract infection in primary care.","authors":"Loic Vanderpoorten, Siebe Vandevelde, Lien De Corte, Jasper Holvoet, Laura Vandevelde, Camille Thys, Eline Thyssen, Lieselot Veekens, Fatou Touré, Jerina Boelens, Stefan Heytens","doi":"10.1080/17843286.2025.2596150","DOIUrl":"10.1080/17843286.2025.2596150","url":null,"abstract":"<p><strong>Objective: </strong>In primary care, urinary tract infections (UTIs) are typically treated empirically, based on the likelihood of specific pathogens and their susceptibility profiles. The goal of this study was to reassess empirical treatment guidelines by comparing he current distribution and susceptibility of uropathogens.</p><p><strong>Method: </strong>Distribution and susceptibility were analyzed and compared with data from three previous surveys conducted in Belgium over the past 25 years. Between August 2020 and February 2022, 137 general practitioners (GPs) collected midstream urine samples from adult female patients with specific cystitis symptoms. The dipslide was inoculated and sent for microbiological analysis.</p><p><strong>Results: </strong>Of the 237 enrolled patients, 201 (85%) had positive cultures. <i>Escherichia coli</i> (74,6%) was the most frequently isolated uropathogen, followed by <i>Staphylococcus saprophyticus (8%), Enterococcus faecalis (6,6%), and Klebsiella pneumoniae</i> (3,3%), confirming the results of the 1995, 2005, and 2015 surveys. The susceptibility of <i>E. coli</i> in 2020 remained 100% for nitrofurantoin and fosfomycin. For ampicillin, there was gradual increase of resistance with a susceptibility in 2020 of 53,5%. The susceptibility rates were 97,5% for levofloxacin and 83,6% for trimethoprim-sulfamethoxazole. Contrary to previous surveys, pivmecillinam was included in the 2020 survey with a susceptibility of 94,8%.</p><p><strong>Conclusion: </strong>Over a 25-year period, the distribution and antimicrobial susceptibility of uropathogens associated with uncomplicated UTIs remained stable. For the first time in Belgium, we assessed <i>E. coli</i> susceptibility to pivmecillinam and found excellent outcomes, suggesting that pivmecillinam could be considered equivalent to standard treatments for uncomplicated UTIs.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"45-53"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145851287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Nocardia farcinica</i> brain abscess in an immunocompetent patient with isolated hemianopsia.","authors":"N Hoornaert, D De Geyter, S Pijpen, R Van der Straeten, J Van Laethem","doi":"10.1080/17843286.2025.2603450","DOIUrl":"10.1080/17843286.2025.2603450","url":null,"abstract":"<p><strong>Background: </strong><i>Nocardia farcinica</i> is an uncommon cause of brain abscess, most often in immunocompromised hosts. Increasingly, cases in immunocompetent individuals are reported, but diagnosis remains challenging and mortality is high.</p><p><strong>Case presentation: </strong>We report a 63-year-old diabetic male with sudden altered mental state and right temporal hemianopsia. Initial CT and FDG-PET/CT suggested a tumour, delaying suspicion of infection. MRI later revealed a cerebral abscess, and stereotactic aspiration yielded purulent material. Direct microscopy showed branching Gram-positive rods; culture identified Nocardia spp. within 1 week. MALDI-TOF confirmed <i>N. farcinica</i>, resistant to meropenem. Empirical ceftriaxone/metronidazole was switched to high-dose trimethoprim-sulfamethoxazole (TMP-SMX) and amoxicillin-clavulanate. The patient developed severe hyperkalaemia (7.7 mEq/L) necessitating TMP-SMX dose reduction and discontinuation of spironolactone. Follow-up MRI at 13 weeks showed complete resolution, with full recovery of visual function. Total therapy duration was 6 months.</p><p><strong>Discussion: </strong>Although high-dose TMP-SMX remains the standard for CNS nocardiosis, toxicity is common. A recent multicenter cohort by Yetmar et al. found that in non-disseminated pulmonary nocardiosis, lower TMP-SMX doses achieved similar outcomes with significantly fewer adverse events, questioning whether universally high doses are necessary. While CNS involvement generally warrants aggressive therapy, our case highlights the need for individualized dosing and close monitoring. Early stereotactic drainage, rapid microbiological work-up, and timely therapy adjustments likely contributed to the excellent outcome in this high-risk patient.</p><p><strong>Conclusions: </strong>This case underscores diagnostic challenges, therapeutic dilemmas, and potential for full recovery in <i>N. farcinica</i> brain abscess. It also emphasizes the importance of balancing efficacy and safety when determining TMP-SMX dosing.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"65-69"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the applicability of the Mini Sarcopenia Risk Assessment questionnaire in Turkish older adult population: a validation study.","authors":"Ozlem Yilmaz, Cihan Kilic, Nefise Seker, Nurdan Şentürk Durmuş, Pinar Kucukdagli, Banu Ozulu Turkmen, Sebnem Sidika Guven, Hanife Usta Atmaca, Mehmet Akif Karan, Gulistan Bahat","doi":"10.1080/17843286.2025.2608781","DOIUrl":"10.1080/17843286.2025.2608781","url":null,"abstract":"<p><strong>Objectives: </strong>To validate the Turkish versions of the Mini Sarcopenia Risk Assessment (MSRA-5 and MSRA-7) questionnaires among older adults.</p><p><strong>Methods: </strong>In this cross-sectional study of 267 participants (aged 65-89 years), MSRA-5 and MSRA-7 were translated and culturally adapted. Reliability was evaluated by Cronbach's α and intraclass correlation coefficient (ICC). Diagnostic accuracy was assessed against national and international sarcopenia criteria using ROC analysis.</p><p><strong>Results: </strong>Cronbach's α was 0.65; ICC for MSRA-5 and MSRA-7 were 0.86 and 0.73, respectively. AUC values were 0.78 (MSRA-5) and 0.74 (MSRA-7) with optimal cut-offs ≤45 and ≤30 (<i>p</i> < 0.001). Sensitivity and NPV for Turkish BMI criterion were 79.7% and 98.8%.</p><p><strong>Conclusion: </strong>The Turkish MSRA-5 and MSRA-7 demonstrated acceptable reliability and validity as preliminary screening tools for sarcopenia among community-dwelling older adults.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"84-94"},"PeriodicalIF":0.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}